The deal will allow Gilead to take on Pionyr’s technology, namely its myeloid-tuning therapy, which rebalances a tumor’s microenvironment to privilege immune-activating cells over immune-suppressing ones. Gilead is focusing on PY314 and PY159, Pionyr’s two preclinical antibodies developed to enhance anti-tumor immunity.
The myeloid-tuning technology exhibits potential to treat patients who are resistant to checkpoint inhibitor therapies.
“The agreement represents important progress as we continue to build out Gilead’s presence in immuno-oncology with innovative and complementary approaches,” Daniel O’Day, Gilead’s CEO, said in a news release.
More articles on pharmacy:
Court invalidates Biogen’s Tecfidera patent
Average pharmacist salaries, by state
Walgreens continues providing vaccinations, implements new safety protocols
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
